Skip to main content

Neuroendocrine Neoplasm clinical trials at UCSF
2 research studies open to eligible people

  • Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery

    open to eligible people ages 18 years and up

    This randomized phase III trial studies cabozantinib S-malate to see how well it works compared with placebo in treating patients with neuroendocrine tumors previously treated with everolimus that have spread to nearby tissues or lymph nodes, have spread to other places in the body, or cannot be removed by surgery. Cabozantinib S-malate is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.

    San Francisco, California and other locations

  • Pembrolizumab in With Liver-Directed or Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors With Metastases

    open to eligible people ages 18 years and up

    This pilot phase II trial studies how well pembrolizumab in combination with liver-directed therapy or Peptide Receptor Radionuclide Therapy (PRRT) works in treating patients with well-differentiated metastatic neuroendocrine tumors and symptomatic and/or progressive tumors that have spread to the liver. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Liver-directed therapies such as, transarterial embolization (TAE), yttrium-90 microsphere radioembolization (RE), and cryoablation may help to shrink tumors that are not being directly targeted. Somatostatin receptor positive (SSTR+) well- diferentiated neuroendocrine tumors (WD-NETs) may benefit from treatment with peptide receptor radionuclide therapy (PRRT) using 177Lu DOTATATE. Giving pembrolizumab in combination with liver-directed therapy or PRRT may work better in treating patients with well-differentiated metastatic neuroendocrine tumors and symptomatic and/or progressive tumors that have spread to the liver.

    San Francisco, California

Last updated: